from 30 Jun 2010 to 31 Dec 2025

Taxonomy & unit: us-gaap: USD
Description: Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary: ELITE PHARMACEUTICALS INC /NV/ quarterly and annual Income Tax Expense (Benefit) in USD history and change rate from 30 Jun 2010 to 31 Dec 2025.
ELITE PHARMACEUTICALS INC /NV/ Income Tax Expense (Benefit) for the quarter ending 31 Dec 2025 was $2,239,910.
ELITE PHARMACEUTICALS INC /NV/ annual Income Tax Expense (Benefit) for 2024 was $4,262,519.
ELITE PHARMACEUTICALS INC /NV/ annual Income Tax Expense (Benefit) for 2023 was $19,645,539.
ELITE PHARMACEUTICALS INC /NV/ annual Income Tax Expense (Benefit) for 2022 was $424,028.
Source SEC data: View on sec.gov

Income Tax Expense (Benefit), Trailing 12 Months (USD)

Income Tax Expense (Benefit), Quarterly (USD)

Income Tax Expense (Benefit), YoY Quarterly Change (%)

Income Tax Expense (Benefit), Annual (USD)

Income Tax Expense (Benefit), YoY Annual Change (%)

ELITE PHARMACEUTICALS INC /NV/ Quarterly Income Tax Expense (Benefit) (USD)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
Q4 2025		$2,239,910^*	+$2,000,735		01 Oct 2025	31 Dec 2025	10-Q	17 Feb 2026	2026	Q3
Q3 2025		$1,987,940^*	+$470,737		01 Jul 2025	30 Sep 2025	10-Q	14 Nov 2025	2026	Q2
Q2 2025		$5,320,501^*	+$5,088,522		01 Apr 2025	30 Jun 2025	10-Q	14 Aug 2025	2026	Q1
Q4 2024		$239,175	+$1,039,788		01 Oct 2024	31 Dec 2024	10-Q	17 Feb 2026	2026	Q3
Q3 2024		$1,517,203^*	+$19,184,587		01 Jul 2024	30 Sep 2024	10-Q	14 Nov 2025	2026	Q2
Q2 2024		$231,979	+$77,027	+50%	01 Apr 2024	30 Jun 2024	10-Q	14 Aug 2025	2026	Q1
Q4 2023	$17,939,854	$800,613	-$839,863	-2140%	01 Oct 2023	31 Dec 2023	10-Q	13 Feb 2025	2025	Q3
Q3 2023	$17,099,991	$17,667,384^*	-$17,678,971		01 Jul 2023	30 Sep 2023	10-Q	14 Nov 2024	2025	Q2
Q2 2023	$578,980	$154,952	+$154,952		01 Apr 2023	30 Jun 2023	10-Q	14 Aug 2024	2025	Q1
Q1 2023	$424,028	$373,191			01 Jan 2023	31 Mar 2023	10-K	01 Jul 2024	2024	FY
Q4 2022		$39,250			01 Oct 2022	31 Dec 2022	10-Q	14 Feb 2024	2024	Q3
Q3 2022		$11,587	+$7,587	+190%	01 Jul 2022	30 Sep 2022	10-Q	14 Nov 2023	2024	Q2
Q2 2022		$0			01 Apr 2022	30 Jun 2022	10-Q	15 Aug 2022	2023	Q1
Q3 2021		$4,000	+$1,500	+60%	01 Jul 2021	30 Sep 2021	10-Q	14 Nov 2022	2023	Q2
Q3 2020		$2,500			01 Jul 2020	30 Sep 2020	10-Q	15 Nov 2021	2022	Q2
Q2 2020		$946,407			01 Apr 2020	30 Jun 2020	10-Q	14 Aug 2020	2021	Q1
Q2 2018	$1,048,329	$0	-$3,000	-100%	01 Apr 2018	30 Jun 2018	10-Q	09 Aug 2018	2019	Q1
Q1 2018	$1,045,329	$3,000	+$3,000		01 Jan 2018	31 Mar 2018	10-K	14 Jun 2018	2018	FY
Q4 2017	$1,048,329	$1,051,329	-$2,921,329		01 Oct 2017	31 Dec 2017	10-Q	11 Feb 2019	2019	Q3
Q3 2017	$1,873,000	$0	$0		01 Jul 2017	30 Sep 2017	10-K	14 Jun 2018	2018	FY
Q2 2017	$1,873,000	$3,000	+$6,000		01 Apr 2017	30 Jun 2017	10-Q	09 Aug 2018	2019	Q1
Q1 2017	$1,867,000	$0	+$520,000		01 Jan 2017	31 Mar 2017	10-K	14 Jun 2018	2018	FY
Q4 2016	$1,347,000	$1,870,000^*	+$1,870,000		01 Oct 2016	31 Dec 2016	10-K	14 Jun 2018	2018	FY
Q3 2016	$523,000	$0	$0		01 Jul 2016	30 Sep 2016	10-K	14 Jun 2018	2018	FY
Q2 2016	$523,000	$3,000	-$3,000		01 Apr 2016	30 Jun 2016	10-K	14 Jun 2018	2018	FY
Q1 2016	$520,000	$520,000	-$517,000	-17233%	01 Jan 2016	31 Mar 2016	10-K	14 Jun 2018	2018	FY
Q4 2015	$3,000	$0	$0		01 Oct 2015	31 Dec 2015	10-K	14 Jun 2018	2018	FY
Q3 2015	$3,000	$0	$0		01 Jul 2015	30 Sep 2015	10-K	14 Jun 2018	2018	FY
Q2 2015	$3,000	$0	$0		01 Apr 2015	30 Jun 2015	10-K	14 Jun 2018	2018	FY
Q1 2015	$3,000	$3,000	+$292,000	+99%	01 Jan 2015	31 Mar 2015	10-K	14 Jun 2017	2017	FY
Q4 2014	$295,000	$0	$0		01 Oct 2014	31 Dec 2014	10-K	14 Jun 2017	2017	FY
Q3 2014	$295,000	$0	-$2,000	-100%	01 Jul 2014	30 Sep 2014	10-K	14 Jun 2017	2017	FY
Q2 2014	$293,000	$0	$0		01 Apr 2014	30 Jun 2014	10-K	14 Jun 2017	2017	FY
Q1 2014	$293,000	$295,000			01 Jan 2014	31 Mar 2014	10-K	15 Jun 2016	2016	FY
Q4 2013		$0	$0		01 Oct 2013	31 Dec 2013	10-K	15 Jun 2016	2016	FY
Q3 2013		$2,000	+$977	+96%	01 Jul 2013	30 Sep 2013	10-K	15 Jun 2016	2016	FY
Q2 2013		$0	-$3,000	-100%	01 Apr 2013	30 Jun 2013	10-K	15 Jun 2016	2016	FY
Q4 2012		$0	$0		01 Oct 2012	31 Dec 2012	10-Q	14 Feb 2013	2012	Q3
Q3 2012		$1,023	+$1,023		01 Jul 2012	30 Sep 2012	10-Q	14 Nov 2012	2012	Q2
Q2 2012		$3,000	+$500	+20%	01 Apr 2012	30 Jun 2012	10-Q	14 Aug 2012	2012	Q1
Q4 2011		$0	-$1,062	-100%	01 Oct 2011	31 Dec 2011	10-Q	14 Feb 2013	2012	Q3
Q3 2011		$0	-$1,040	-100%	01 Jul 2011	30 Sep 2011	10-Q	14 Nov 2012	2012	Q2
Q2 2011		$2,500	+$2,500		01 Apr 2011	30 Jun 2011	10-Q	14 Aug 2012	2012	Q1
Q4 2010		$1,062			01 Oct 2010	31 Dec 2010	10-Q	14 Feb 2012	2011	Q3
Q3 2010		$1,040			01 Jul 2010	30 Sep 2010	10-Q	14 Nov 2011	2011	Q2
Q2 2010		$0			01 Apr 2010	30 Jun 2010	10-Q/A	19 Aug 2011	2011	Q1

ELITE PHARMACEUTICALS INC /NV/ Annual Income Tax Expense (Benefit) (USD)

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
2024	$4,262,519^*	+$23,908,058		01 Apr 2024	31 Mar 2025	10-K	30 Jun 2025	2025	FY
2023	$19,645,539^*	-$20,069,567		01 Apr 2023	31 Mar 2024	10-K	30 Jun 2025	2025	FY
2022	$424,028	+$2,160,465		01 Apr 2022	31 Mar 2023	10-K	01 Jul 2024	2024	FY
2021	$1,736,437^*			01 Apr 2021	31 Mar 2022	10-K	29 Jun 2023	2023	FY
2018	$676,016	+$369,813	+35%	01 Apr 2018	31 Mar 2019	10-K	29 Jun 2020	2020	FY
2017	$1,045,829	+$821,785		01 Apr 2017	31 Mar 2018	10-K	21 Jun 2019	2019	FY
2016	$1,867,614^*	-$1,347,162		01 Apr 2016	31 Mar 2017	10-K	14 Jun 2018	2018	FY
2015	$520,452	-$517,203	-15919%	01 Apr 2015	31 Mar 2016	10-K	14 Jun 2018	2018	FY
2014	$3,249	+$289,362	+99%	01 Apr 2014	31 Mar 2015	10-K	14 Jun 2017	2017	FY
2013	$292,611			01 Apr 2013	31 Mar 2014	10-K	15 Jun 2016	2016	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.